Dataset Information


Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?

ABSTRACT: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone-R-CHOP), which allows a 60% overall survival (OS) rate, but up to 40% of patients experience relapse or refractory (R/R) disease. With the purpose of searching for new clinical parameters and biomarkers helping to make a better DLBCL patient characterization and stratification, in the last years a series of large discovery genomic and transcriptomic studies has been conducted, generating a wealth of information that needs to be put in order. We reviewed these researches, trying ultimately to understand if there are bases offering a roadmap toward personalized and precision medicine also for DLBCL.


PROVIDER: S-EPMC7017344 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2008-01-01 | S-EPMC2675107 | BioStudies
2012-01-01 | S-EPMC3496956 | BioStudies
2019-01-01 | S-EPMC6445782 | BioStudies
1000-01-01 | S-EPMC3204085 | BioStudies
2019-01-01 | S-EPMC6755150 | BioStudies
2019-01-01 | S-EPMC6497517 | BioStudies
2020-01-01 | S-EPMC7099333 | BioStudies
2015-01-01 | S-EPMC4441579 | BioStudies
2020-01-01 | S-EPMC6960034 | BioStudies
2020-01-01 | S-EPMC7463683 | BioStudies